Tahoe key facts
as of Oct 2026- Operator of a biotech company intended to combine data to find better targets and drugs that can treat patients.
- Tahoe is valued at approximately $131.0M as of Oct 2026, set at its early-stage round, Aug 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $50.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($35.0M) in Aug 2025.
- Notable investors include General Catalyst, Mubadala Investment Company, AWS Startups, Wing Venture Capital, Amplify Partners — 12 tracked in total.
- Status: Privately Held (backing).
Valued at $131.0M at its early-stage round, Aug 2025. Nothing has traded since.
- ·The complete investor list: 12 names
- ·Watch Tahoe: the Monday email on marks, rounds and moves
Tahoe funding rounds
1 roundsWho backs Tahoe
12+Tahoe valuation
Tahoe was valued at $131 million at its early-stage round in Aug 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Tahoe raised?
Tahoe has raised $50 million in total; 1 of its rounds is on record. The largest on record was a $35 million Series A in Aug 2025.
Tahoe investors
12 investors are on record for Tahoe, including General Catalyst, Mubadala Investment Company, AWS Startups and Wing Venture Capital. By type, the record holds 9 venture capital firms. The Series A in Aug 2025 drew 8 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Alchemab Therapeutics ($138 million), Imbria Pharmaceuticals ($132 million) and Vivace Therapeutics ($125 million).
About Tahoe
Operator of a biotech company intended to combine data to find better targets and drugs that can treat patients. The company's platform engages in generating scalable, single-cell precision to capture the context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays, enabling doctors to improve the failure rate of drugs in clinical trials.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2022
- Employees
- 25
- Website
- tahoebio.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.